Accelerating Biomarker Discovery Through Electronic Health Records, Automated Biobanking, and Proteomics.
Academic Medical Centers
Acceleration
Aged
Automation
/ methods
Biological Specimen Banks
/ organization & administration
Biomarkers
/ blood
Cohort Studies
Electronic Health Records
/ organization & administration
Female
Heart Failure
/ blood
Humans
Male
Middle Aged
Proportional Hazards Models
Prospective Studies
Proteomics
/ organization & administration
Reproducibility of Results
Risk Assessment
Sensitivity and Specificity
Thrombospondins
/ blood
biomarkers
electronic health records
heart failure
proteomics
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
07 05 2019
07 05 2019
Historique:
received:
28
08
2018
revised:
22
01
2019
accepted:
23
01
2019
entrez:
4
5
2019
pubmed:
3
5
2019
medline:
4
3
2020
Statut:
ppublish
Résumé
Circulating biomarkers can facilitate diagnosis and risk stratification for complex conditions such as heart failure (HF). Newer molecular platforms can accelerate biomarker discovery, but they require significant resources for data and sample acquisition. The purpose of this study was to test a pragmatic biomarker discovery strategy integrating automated clinical biobanking with proteomics. Using the electronic health record, the authors identified patients with and without HF, retrieved their discarded plasma samples, and screened these specimens using a DNA aptamer-based proteomic platform (1,129 proteins). Candidate biomarkers were validated in 3 different prospective cohorts. In an automated manner, plasma samples from 1,315 patients (31% with HF) were collected. Proteomic analysis of a 96-patient subset identified 9 candidate biomarkers (p < 4.42 × 10 A novel strategy integrating electronic health records, discarded clinical specimens, and proteomics identified 2 biomarkers that robustly predict HF across diverse clinical settings. This approach could accelerate biomarker discovery for many diseases.
Sections du résumé
BACKGROUND
Circulating biomarkers can facilitate diagnosis and risk stratification for complex conditions such as heart failure (HF). Newer molecular platforms can accelerate biomarker discovery, but they require significant resources for data and sample acquisition.
OBJECTIVES
The purpose of this study was to test a pragmatic biomarker discovery strategy integrating automated clinical biobanking with proteomics.
METHODS
Using the electronic health record, the authors identified patients with and without HF, retrieved their discarded plasma samples, and screened these specimens using a DNA aptamer-based proteomic platform (1,129 proteins). Candidate biomarkers were validated in 3 different prospective cohorts.
RESULTS
In an automated manner, plasma samples from 1,315 patients (31% with HF) were collected. Proteomic analysis of a 96-patient subset identified 9 candidate biomarkers (p < 4.42 × 10
CONCLUSIONS
A novel strategy integrating electronic health records, discarded clinical specimens, and proteomics identified 2 biomarkers that robustly predict HF across diverse clinical settings. This approach could accelerate biomarker discovery for many diseases.
Identifiants
pubmed: 31047008
pii: S0735-1097(19)33945-2
doi: 10.1016/j.jacc.2019.01.074
pmc: PMC6501811
mid: NIHMS1526156
pii:
doi:
Substances chimiques
Biomarkers
0
Thrombospondins
0
thrombospondin 2
0
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2195-2205Subventions
Organisme : NIH HHS
ID : S10 OD017985
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL128928
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL140074
Pays : United States
Organisme : NHLBI NIH HHS
ID : K12 HL109019
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL132320
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL133870
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Références
J Am Coll Cardiol. 2004 Feb 4;43(3):423-8
pubmed: 15013125
Circ Res. 2004 Sep 3;95(5):515-22
pubmed: 15284191
Eur J Heart Fail. 2005 Aug;7(5):787-91
pubmed: 15916919
J Am Coll Cardiol. 2006 Sep 19;48(6):1217-24
pubmed: 16979009
Nat Cell Biol. 2008 May;10(5):527-37
pubmed: 18425119
Clin Pharmacol Ther. 2008 Sep;84(3):362-9
pubmed: 18500243
Heart. 2009 Sep;95(18):1508-13
pubmed: 19525245
Circulation. 2009 Oct 20;120(16):1585-97
pubmed: 19805649
J Am Coll Cardiol. 2010 Nov 16;56(21):1712-9
pubmed: 21070922
PLoS One. 2010 Dec 07;5(12):e15004
pubmed: 21165148
Eur J Cardiovasc Prev Rehabil. 2011 Aug;18(4):607-14
pubmed: 21450636
J Mol Cell Cardiol. 2011 Sep;51(3):318-28
pubmed: 21624372
PLoS Comput Biol. 2011 Aug;7(8):e1002141
pubmed: 21901084
Am J Hum Genet. 2011 Oct 7;89(4):529-42
pubmed: 21981779
N Engl J Med. 2011 Nov 10;365(19):1758-9
pubmed: 22047518
Mol Cell Proteomics. 2012 Jun;11(6):M111.014340
pubmed: 22301387
Cardiovasc Res. 2012 Apr 1;94(1):115-24
pubmed: 22308237
Am Heart J. 2012 Dec;164(6):825-34
pubmed: 23194482
Clin Pharmacol Ther. 2013 Feb;93(2):204-11
pubmed: 23281421
Eur Heart J. 2013 Jun;34(22):1651-62
pubmed: 23349297
Exp Ther Med. 2013 Mar;5(3):937-941
pubmed: 23408510
PLoS One. 2013 Aug 05;8(8):e70459
pubmed: 23940579
Circ J. 2014;78(4):903-10
pubmed: 24500070
Sci Transl Med. 2014 Apr 30;6(234):234cm3
pubmed: 24786321
Heart Vessels. 2016 Jan;31(1):52-9
pubmed: 25150586
Clin Res Cardiol. 2015 May;104(5):380-7
pubmed: 25408112
J Pers Med. 2015 May 14;5(2):140-52
pubmed: 26110578
Circulation. 2015 Sep 1;132(9):852-72
pubmed: 26195497
J Biomed Res. 2015 Mar 02;30:null
pubmed: 26423730
JAMA. 2016 Jan 5;315(1):47-57
pubmed: 26746457
Int J Cardiol. 2016 Jun 1;212:364-8
pubmed: 27057957
Circulation. 2016 Jul 26;134(4):270-85
pubmed: 27444932
J Am Coll Cardiol. 2016 Dec 27;68(25):2819-2830
pubmed: 28007144
Circulation. 2017 Apr 25;135(17):1651-1664
pubmed: 28438806
Pharmacogenet Genomics. 2017 Jul;27(7):247-254
pubmed: 28542097
Circulation. 2018 Mar 13;137(11):1158-1172
pubmed: 29258991
Diagnostics (Basel). 2018 Oct 08;8(4):null
pubmed: 30297602